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Morphological criteria for the diagnosis of intraductal proliferative lesions of the breast have been an object of research and much
controversy, and its terminology is rather confusing. Knowledge of the molecular aspects of this disease probably necessitates
further research to clarify if these entities can be identiﬁed as breast cancer precursors or as a malignant preinvasive disease. These
issues are of great interest not only for their biological implications, but also to the clinician who must understand the disease
and direct therapies. Molecular studies have shown that epitheliosis (usual ductal hyperplasia) is not monoclonal, while malignant
lesions (atypical ductal hyperplasia, ﬂat epithelial atypia, low-grade and high-grade intraductal carcinoma) constantly show these
characteristics. These malignant lesions, classiﬁed with a DIN grading system (ductal intraepithelial neoplasia), are not obligate
precursors of invasive ductal carcinoma and do not represent diﬀerent evolving grades in a linear model of cancerogenesis. Breast
cancerogenesis probably has diﬀerent pathways with diﬀerent morphologic precursors.
1.Introduction
Intraductal proliferative lesions (IPLs) of the breast are
conﬁned to the duct-lobular system, originating from the
terminalduct-lobularunit(TDLU)withdiﬀerentcytological
and architectural patterns of proliferation. They are charac-
terized by an increase in the number of cells perpendicular
to the basement membrane resulting in total alteration and
distension of the normal unit structure of the breast without
increasing in number [1].
Bothalobularandaductaltypeofepithelialproliferation
of TDLU are recognized. While the ﬁrst type is quite
monomorphic, intraductal proliferations show a wide vari-
ety of heterogeneous cytological aspects and architectural
patterns.
In the past several decades, there has been a wide discus-
sion among pathologists worldwide regarding classiﬁcation
and grading of IPLs, with the aim to establish various
risk categories. Despite these eﬀorts, a high interobserver
variability among pathologists regarding the diagnosis of
IPLs as well established [2].
Criteria for diagnosis of IPLs by morphological means
(Hematoxylin and Eosin and immunohistochemistry stains)
are both qualitative (cytological and architectural changes),
and quantitative. Diagnostic variability is not only due to
interpretation of diﬀerent patterns, but also to the diﬃculty
in recognizing atypical cells isolated or in small clusters in
TDLU.
In this regard, there are several open questions in the
literature, including the minimum threshold for grading,
the risk of progression for diﬀerent type of lesions, and the
relationships between normal epithelium, IPLs, and invasive
ductal carcinoma (IDC). Furthermore, it is unclear whether
diﬀerent types of IPLs are progressive steps of the same
process or represent independent lesions leading to diﬀerent
malignancies.Inthelastfewyears,therehavebeennumerous
studies in this ﬁeld, and several answers have been suggested
to these questions.2 International Journal of Surgical Oncology
These issues are of great interest not only to those in-
volved in basic research, but also to the clinicians, because
eachtypeoflesionhasdiﬀerentpropensityforprogressionto
local relapse and invasive disease. Therefore, understanding
thebiologyoftheselesionsisparamount,andwillcontribute
to a better delineation of appropriate guidelines for surgical
treatment, as well as adjuvant and diagnostic recommenda-
tions.
2.Terminology andHistoricalAspects
The term utilized by Azzopardi [3] for benign epithelial
hyperplasia was epitheliosis. This term found little agreement
among pathologists and has gained much wider acceptance
in Europe than in North America. The alternative terms
in the past were papillary proliferation and papillomatosis,
because it can form “tongue-like” projection into ductal
lumina, but without the connective core in papillae seen in
papillarylesionsofotherorgans.Todate,epitheliosisappears
a correct term because it includes the various patterns
of benign proliferation, as fenestrated, solid, or papillary
aspects. In recent years, the term Usual Duct Hyperplasia
(UDH) [4] has been utilized for these lesions.
Epitheliosis is a condition that has to be distinguished
from in situ well-diﬀerentiated, low-grade carcinoma (LG-
DCIS). The criteria for diagnosis have been well described by
Azzopardi [3]. Two cell types are distinguishable in epithe-
liosis, epithelial, and myoepithelial, which have divergent
diﬀerentiation. Immunohistochemical stains (p63, actin,
calponin) are useful to detect myoepithelial cells in the
lesion (Figures 1(a) and 1(b)). In epitheliosis, there is little
distension of TDLU, few calciﬁcations (not in granular form
in necrotic debris), and absence of necrosis. A particularly
complex pattern is the inﬁltrating epitheliosis [3, 5], previ-
ously described as sclerosing adenosis with pseudo-inﬁltration
[6].Theso-calledsclerosingpapillaryproliferationofFenoglio
and Lattes [7] probably represents the same entity. The
hyperplastic epithelial structures are irregulars, distorted by
an elastotic and sclerotic stroma.
The hallmarks of LG-DCIS are architectural and cyto-
logical aspects. Myoepithelial cells cover the neoplastic ducts
but are not present in the neoplastic proliferation (Figures
3(a) and 3(b)). Intraluminal or intraepithelial calciﬁcation,
as calciﬁc bodies, are frequent. The solid form of LG-
DCIS has the same cytology. Another type of LG-DCIS was
referred to by Azzopardi [3]a stype 2 or monomorphous
clinging carcinoma (Figure 2). This pattern is particularly
diﬃcult to recognize, because the change is only cytological.
One or few layers of columnar, atypical cells, deﬁne the
lumen of variously larger TDLU. Pathologists have been
much more reluctant to accept Azzopardi’s second type of
clinging carcinoma as a type of DCIS, particularly in the
United States. This type of LG-DCIS is referred to also
as atypical cystic lobules, atypical lobules type A, atypical
columnarchange,[8]and,inrecentyears,ﬂatepithelialatypia
(FEA) [4].
A “borderline” entity, between UDH and LG-DCIS, is
controversial. Historically, there are two opposing ap-
proaches. The ﬁrst viewpoint entails sharp demarcation
between UDH and LG-DCIS, without intermediate lesions.
Azzopardi said “...names like atypical hyperplasia should be
avoided as far as possible.” The second viewpoint entails
the existence of a continuum between hyperplasia and LG-
DCIS, with diﬀerent risk of progression for diﬀerent grades
of proliferation and atypia. Page et al. [9, 10] established
two grades of hyperplasia, including atypical hyperplasia.
Atypical hyperplasia is diagnosed when some features of
LG-DCIS are present but other are lacking. When the duct
is not completely involved, or when cytological appearance
does not meet all the criteria of LG-DCIS. Other grading
systems of IPLs suggested diﬀerent grading of proliferation
and atypia in borderline lesions [11]. The criteria proposed
for the diagnosis of atypical ductal hyperplasia (ADH)
are diﬀerent: (i) lesions with cytological and architectural
patterns of LG-DCIS are present, but both are not present
in full ﬂower; (ii) lesions with cytologic feature of LG-
DCIS but lacking the typical growth pattern; (iii) lesions
with cytological and architectural patterns of LG-DCIS but
measuring in aggregate less than 2mm [1]. Tavassoli [4]
accepted the last criteria.
Intermediate grade DCIS (IG-DCIS) and high-grade
DCIS (HG-DCIS) are obvious neoplastic lesions, graded
by nuclear grade, necrosis, and architectural patterns. IG-
DCIS has solid, papillary, or cribriform growth patterns,
cytologically similar to those of LG-DCIS but with intralu-
m i n a ln e c r o s i s( Figure 4(a)) or with intermediate cytological
grade (Figure 4(b)), with or without necrosis. HG-DCIS
has highly atypical cells proliferating as a single layer, or
with papillary, cribriform, or solid pattern, usually with
intraluminal necrosis. The HG-DCIS with solid pattern and
large intraductal necrosis is referred to as comedocarcinoma
(Figure 5). Typical granular calciﬁcations on necrosis are
present.
Rosai [2] proposed a terminology such as mammary
intraepithelial neoplasia (MIN), like CIN of uterine cervix,
for subjectivity and high degree of variability in interpreta-
tion of IPLs, disagreement about the criteria for deﬁnition
of borderline lesions, and risk of progression of all types
of IPLs. Afterwards this concept has been drawn as ductal
intraepithelial neoplasia.
3.DINSystem
Tavassoli [1] proposed to comprise all the IPLs in a
single category, termed DIN, with various subtypes. This
initial work by Tavassoli included epitheliosis or intraductal
hyperplasia as DIN1a, because the risk of developing an
invasive carcinoma was 1.5–2 times higher than in the
generalpopulation. IntheWHObook [4],UDHisseparated
by DIN, which includes FEA (DIN1A), ADH (DIN1B), LG-
DCIS (DIN1C), IG-DCIS (DIN2), and HG-DCIS (DIN3)
(Table 1).
DIN System has some advantages. It diminishes the
dualism cancer/no cancer, retains separation of all diﬀerent
subcategories but places LG-DCIS in the same group of
ADH, because it considers the diﬀerences between these
lesions quantitative, not qualitative. It eliminates the term
cancer, diminishing the associated anxiety and emotionalInternational Journal of Surgical Oncology 3
(a) (b)
Figure 1: H.E. and immunoreaction for SM-actin—epitheliosis (usual ductal hyperplasia). Intraductal proliferation with irregular, “slit-
like” lumina. The immunoreaction shows myoepithelial cells (arrows) surrounding the duct and in the proliferation.
Figure 2: H.E.—ﬂat epithelial atypia (DIN1a)—large TDLU with
one to three layers of atypical ductal cells and mitosis.
stress, and it incorporates the monomorphus clinging DCIS
(FEA) in the same group of ADH and LG-DCIS.
The majority of the participants in the WHO Working
Group were in favour of maintaining the traditional termi-
nology with the new DIN System [4]. This fact shows well
the disagreement and scepticism of pathologists.
4.GeneticandMolecularFindings
In the last twenty years, there have been numerous studies
to search for genetic and molecular diﬀerences or similarities
between the various forms of IPLs, heterogeneous in their
cytological and architectural characteristics, and between
IPLs and normal TDLU and IDC. Sometimes the results
seem conﬂicting, but a more careful analysis reveals very
interestinginformationabouthistogenesis,evolution,degree
of progression, and invasiveness. The apparent contra-
dictions are related to the diﬀerent methods employed,
with the diﬃculty of performing studies on very small
lesions, with the possibility of contamination by normal
tissue around the lesion. Laser capture microdissection has
reduced these problems, and the possibility of using very
advanced methods like comparative genomic hybridization
on paraﬃn-embedded tissues has brought to utilize archive
material [12].
A multitude of methods have been utilized: immuno-
histochemistry (IHC), in situ hibridization (ISH), analysis
of loss of heterozygosity and allelic imbalance (AI), Com-
parative Genomic hybridization (CGH), cDNA microarrays
(MA), and Proteomics Analysis (PA). The purposes of
these methods are the study of growth characteristics, the
expression of oncogenes, tumor suppressor genes, and other
molecules, comparison of LOH and AI between the various
forms of IPLs, and IPLs versus normal TDLU, IPLs versus
IDC.
4.1. Growth Characteristics. The growth of any hyperplastic
or neoplastic lesion is a balance between proliferation and
cell death (apoptosis). Many researchers have studied the
Proliferation Index (PI) with IHC, using antibodies marking
cellular proliferative cycle like Ki67 [13]. In premenopausal
women, the PI of the normal TDLU varies in diﬀerent phases
of the menstrual cycle. In luteal phase, it is higher than in
proliferative phase. The median PI in normal TDLU is 2%,
in ADH it is 5%, in DCIS it is 5%. LG-DCIS and FEA have
a median PI of 5%, while in HG-DCIS it is 20%. In any case
there is a continuous range from 1% and 70% from very well
and poorly diﬀerentiated lesions.
ADH has a lower rate of apoptosis (0,3% versus 0,6%)
andhigherPIthannormalTDLU;DCIShashigherapoptosis
(5%) and PI than normal TDLU and ADH. Apoptosis varies
from 1% to 5% among LG-DCIS and HG-DCIS, and it
represents a continuous variable [14]. Higher cellular death
in high-grade lesions means that the growth is a complex
phenomenon.HG-DCIShaslargepositivegrowthimbalance
with a high cellular death. Disturbance of the equilibrium
between cell proliferation and cell death is the result of
numerous alterations of growth regulating mechanisms
involving sex hormones, oncogenes, and tumor suppressor
genes.4 International Journal of Surgical Oncology
(a) (b)
Figure 3:H.EandimmunoreactionforSM-actin—lowgradeductalinsitucarcinoma(DIN1c).Cribriformtypeofintraductalproliferation
with round, regular lumina, monomorphic round nuclei. Myoepithelial cells surround the duct but are not in the proliferation.
(a) (b)
Figure 4: H.E.—intermediate grade ductal in situ carcinoma (DIN2). Obvious cribriform ductal in situ carcinoma with necrosis
(Figure 4(a)—arrow) and intermediate cytological grade.
4.2. Sex Hormones, Oncogenes, and Tumor Suppressor Genes.
Estrogens, through Estrogen Receptor (ER), play a central
role in growth and diﬀerentiation of normal TDLU epithe-
lium, stimulating cell proliferation and regulating expression
of other genes, like Progesteron Receptor (PgR) [15]. Two
types of ER are described: ERα and ERβ.E R α is the more
studied molecule. 90% of normal TDLU express ER in an
average 30% of cells [14]. There is a change of expression
during the menstrual cycle: in the luteal phase, the rate of
positive cells is higher (40% versus 20%). In postmenopausal
women, the rate is higher (50%). Nearly all cells of ADH
express ER. ER is expressed in 75% of DCIS; 100% in LG-
DCIS, nearly all cells, and 30% in HG-DCIS, usually in a rate
of cells [14, 16].
Many molecules are studied in IPLs, but the majority of
studies have not been validated [17]. Exceptions are c-erbB2
(neu) and p53.
In IDC, c-erbB2 (neu) is overexpressed or ampliﬁed in
10–20% of cases, generally HG-IDC. It plays a role in cell
proliferation, is related to poor clinical outcome, is a pre-
dictive marker for responsiveness to various therapies, and
promotes cell mobility [18]. In recent years, it has been one
of the more studied markers in breast cancer, because it
is a target for trastuzumab therapy. Normal TDLU, UDH,
ADH, and FEA do not express c-erbB2 (neu). LG-DCIS and
intermediate grade express neu in less than 10% of cases,
whereasinHG-DCISitisoverexpressedin60%ofcases[19].
The more utilized method to detect expression of p53
is IHC, which is a surrogate assay for detecting mutations,
because a gene with missense mutations codiﬁes for inacti-
vate protein. This abnormal inactive protein is accumulated
in very high levels in the nucleus of neoplastic cells, and
it is detectable by IHC [20]. 30% of IDC overexpress p53,
and it is related to aggressive biological features and poor
clinical outcome. Normal TDLU, UDH, and ADH do not
overexpress p53, apart from in the Li-Fraumeni syndrome,
characterized by inherited mutations. In DCIS p53 correlatesInternational Journal of Surgical Oncology 5
Figure 5: H.E.—high-grade ductal in situ carcinoma (DIN3). Solid
intraductal carcinoma with high cytological grade and necrosis
(comedocarcinoma) and numerous mitosis.
with diﬀerentiation. It is rare in LG-DCIS and common
(40%) in HG-DCIS [21].
Clarketal.[22]foundbyIHCanalysisontissuemicroar-
ray (TMA) the same molecular classes in DCIS as in IDC
[23, 24], but with diﬀerent frequency. Basal-like phenotype
is rare in DCIS; c-erbB2 is more frequently expressed in
Luminal-like DCIS than in IDC (13,2% versus 5,2%). The
mitochondrial antiapoptotic protein bcl2 is up-regulated in
LG (G1-G2) Luminal-type DCIS. The same results are in the
study of Tamimi et al. [25]. Livasy et al. [26] found a higher
frequency of Basal phenotype in DCIS.
Other genes and proteins are studied in IPLs and com-
pared with IDC.
Ma et al. [27] studied ﬁve genes with quantitative RT-
PCR in ADH and DCIS, upregulated or downregulated in
IDC. These genes were altered in the same rate in ADH,
DCIS, and IDC: for example, CRIP1 was upregulated in
7/8 ADH, in 27/30 DCIS and in 23/25 IDC, and ELF5 was
downregulated in 7/8 ADH, in 28/30 DCIS and 25/25 IDC.
Signiﬁcant alterations in gene expression of ADH are main-
tained in the later stages of DCIS and IDC. Furthermore, to
characterize the molecular link between DCIS and IDC, the
study recognizes other clusters of genes related to inﬁltrative
potential. These genes establish diﬀerent patterns of gene
expression among DCIS, which reﬂect diﬀerent invasive
potential, and there is a gene signature of DCIS, like for IDC
[28].
Gillett et al. [29] studied expression of Cyclin D1 in ADH
and DCIS. In IDC, expression of Cyclin D1 is more frequent
in well diﬀerentiated and ER+ cases. ADH does not express
Cyclin D1, but it is ER+ like LG-DCIS: in DCIS Cyclin D1 is
over-expressed in 64% of cases, and it is not related to grade
or to ER expression.
Schuetz et al. [30] studied genes of epithelial mesenchy-
mal Transition (EMT) and other genes candidates to cause
invasion and metastases [31]. These genes (Twist1, SPARC,
MMP13, MMP11, BPAG1) are markers of transition from
DCIS to IDC. Some of the proteins codiﬁed by these genes
are very interesting: for example, BPAG1 is expressed in
hemidesmosomes connecting epithelial cells to basement
Table 1: Terminology of IPLs.
DIN system Traditional terminology
Usual ductal
hyperplasia
(UDH)
Epitheliosis
Inﬁltrating epitheliosis
Papillomatosis
Sclerosing adenosis with pseudoinﬁltration
Sclerosing papillary proliferation
DIN1a
Clinging carcinoma monomorphus or type 2
Flat epithelial atypia
Atypical cystic lobules
Atypical lobules type A
Atypical columnar change
DIN1b Atypical ductal hyperplasia (ADH)
DIN1c Low-grade ductal carcinoma in situ (LG-DCIS)
DCIS grade 1
DIN2
Intermediate-grade ductal carcinoma in situ
(IG-DCIS)
DCIS grade 2
DIN3 High-grade ductal carcinoma in situ (HG-DCIS)
DCIS grade 3
membrane. IDC cells do not contain hemidesmosomes
and BPAG1 is downregulated. Matrix metalloproteinases
(MMPs) can degrade diﬀerent components of extracellular
matrix, including laminin, ﬁbronectin, collagen, and elastin,
and are upregulated in HG-DCIS.
Porter et al. [32] and Kretschmer et al. [33]f o u n d
several genes of IDC up-regulated in DCIS using SAGE
(Serial Analysis of Gene Expression), TMA, quantitative RT-
PCR, and IHC. Some of these genes are not related to
diﬀerentiation grade (MUC1, SBP1) and probably play a role
in early cancerogenesis. Other proteins, like the psoriasin
(S-100A7), a calcium-binding protein that regulates cell
cytoskeleton and motility, are present in comedo-type HG-
DCIS.
4.3. LOH and Allelic Imbalance (AI). Two types of studies
are performed: the ﬁrst on IPLs in their pure form and
the second on IPLs with synchronous IDC in the same
breast. The strategy of the last type is to identify alterations,
which may be important in the invasiveness [17]. Generally,
IPLs with synchronous invasive cancer share more frequent
genetic alterations with IDC than pure forms. For example,
a marker on chromosome 11p (D11S988) is more frequent
in all IPLs close to IDC than in IPLs without cancer
[34]: morphologically normal TDLU close to IDC also
shared rarely some LOH with cancer [35]. O’Connell et
al. [34], assessing LOH to 15 loci on 12 chromosomes,
found that 50% of ADH shared their LOH phenotypes with
synchronous IDC, providing novel and compelling genetic
evidencethatADHisadirectprecursorofIDC.Manystudies
of DCIS have shown that nearly all lesions share several
identical AI with synchronous IDC, providing convincing if
not surprising evidence that they are evolutionarily related
too [34–38]. Synchronous DCIS and IDC may occasionally6 International Journal of Surgical Oncology
showdistinctAIs,suggestingthattheremayalsobedivergent
aspects to their evolution [25].
There are numerous studies on LOH in IPLs without
invasive cancer.
Allelic Imbalance in UDH is rare: Lakhani et al. [39]
found alterations in 0–13% of studied loci, frequently in 17q;
Deng et al. [35]f o u n da l t e r a t i o n si nd i ﬀerent loci in 0–15%.
Moinfar et al. [40] found AI on 77% of FEA, at least
in one locus 11q, 16q, and 3p. 11q and 16q are frequently
involved in tubular carcinoma.
Morphological overlap between ADH and LG-DCIS is
reﬂected at molecular level. Up to 50% of ADH contains one
or more AIs among 30 genetic loci [35, 39], and they are the
same of DCIS.
CGH analysis of DCIS has demonstrated a large number
of alterations, including gains of 1q, 5p, 6q, 8q, 17q, 19q,
20p, 20q, and Xq, and losses of 2q, 5q, 6q, 8p, 9p, 11q, 13q,
14q, 16q, 17p, 17q, and 22q [35, 41, 42]. Some AI are more
frequent and constitute hot spots: loss in 11q, 16q, 17p and
17q.
Rosenberg et al. [43] studied a series of 15 microsatellite
lociinADHandfoundmonoclonalmicrosatellitealterations
in 40% of cases in more than one locus, suggesting that a
genetic instability plays an early role in cancer progression.
Wiechmann and Kuerer [44] characterize the diﬀer-
ences between LG-DCIS and HG-DCIS and their risk of
progression in IDC by means of the expression of steroid
receptor (LG-DCIS is frequently ER/PgR positive), growth
characteristics (Ki67 is lower in LG-DCIS than in HG-
DCIS), expression of c-erbB2 (frequent in HG-DCIS, rare
in LG-DCIS), bcl2 and p53 (the ﬁrst over-expressed in
LG-DCIS, the second frequently mutated in HG-DCIS),
expression of psoriasin (S-100A7) and metalloproteinases
(MMPs) (upregulated in HG-DCIS), and allelic imbalance
(LG-DCIS has frequently gain of 1q and loss of 16q, whereas
HG-DCIS shows frequently 17q12 and 11q13 ampliﬁcation).
In Table 2 are reported the more frequent alterations in
IPLs and IDC.
5. Discussion
One of the most controversial topics about breast pathology
concerns IPL, with a wide range of phenotypic mani-
festations from epitheliosis to DCIS. Page et al. [9, 10]
have suggested that there is a continuum between these
two extremes, with an intermediate condition called ADH.
Azzopardi [3], on the other hand, draws a sharp line of
demarcation between hyperplastic and neoplastic lesions,
and he stigmatizes: “...names like “atypical hyperplasia”
should be avoided as far as possible”. He himself describes a
particular type of DCIS called clinging carcinoma. The low-
grade clinging carcinoma (type 2 according to Azzopardi)
and columnar change is named also ﬂat epithelial atypia
(FEA).
High interobserver variability among experienced
pathologists in ADH interpretation is reported [2], mainly
related to diﬀerent proposed criteria. WHO book [4]
suggests the use of dimensional criteria of Tavassoli [1]:
Table 2: “hot spots” in IPLs—more frequent allelic imbalances
reported.
Gains Losses
UDH rare rare
ADH 1q, 16p 11p, 11q, 16q, 17p
FEA — 3p, 11q, 16q
DCIS
1q (LG-DCIS), 5p,
6q, 8q, 17q, 19q,
20p, 20q
(HG-DCIS),X q
2q, 5q, 6q, 8p, 9q, 11q
(HG-DCIS),13q (HG-DCIS), 14q,
16q (LG-DCIS), 17p, 17q
(HG-DCIS), 22q
ADH is a lesion with cytological and architectural pattern of
LG-DCIS measuring in aggregate less than 2mm.
The various IPLs have diﬀerent risk of progression:
UDC has two folds, ADH four folds, and LG-DCIS ten
f o l d sc o m p a r e dt on o r m a lb r e a s t[ 9, 10]. At the molecular
level, rarely UDH shows allelic imbalance (AI) for one
gene, whereas ADH, FEA, and LG-DCIS show frequent
AIs for many genes [34–39]. Expression of high-molecular-
weight cytokeratin is diﬀerent between UDH and other IPLs:
UDH consistently displayed the presence of a population
of cytokeratin 5/6-expressing basal-type cells within the
proliferative lesion, whereas ADH and LG-DCIS lacked
cytokeratin 5/6-positive cells. A subset of HG-DCIS express
cytokeratin 5/6: it is probably the precursor of Basal-like IDC
[42]. The studies about growth characteristics (proliferative
index and apoptosis) and about expression of diﬀerent
molecules like ER, oncogenes, and tumor suppressor genes
display a substantial diﬀerence between UDH and other
IPLs. ADH, FEA, and LG-DCIS, on the other hand, shares
many biological characteristics with IDC [13, 14, 16, 17, 45],
and microsatellite analysis shows monoclonality and genetic
instabilityinADH[43].ThissupportstheconceptthatUDH
is a not malignant lesion, the opposite to other IPLs. ADH,
FEA and LG-DCIS can be set in the same group of pre-
invasive breast neoplastic lesions. DIN system, as well as
proposedbyTavassoli[4],includesADH,FEAandDCIS,not
UDH.
Several data support the concept that diﬀerent types of
DCIS show diﬀerent genetic alterations [41, 42]. Alterations
at 16q are much more frequent in LG-DCIS than in HG-
DCIS, in which alterations at 13q, 17q, and 20q are more
frequent [4, 6, 7, 10]. Similar ﬁndings are in invasive
carcinomas of low and high grade [41, 42, 46–48]. On the
other hand, LG-DCIS share many molecular alterations with
ADH [35, 39] and LG-IDC, and also the few studies on FEA
[40] show alterations similar to LG-IDC, in particular with
a very well-diﬀerentiated IDC (tubular carcinoma). These
molecular studies reﬂect the same morphological ﬁndings:
(i) it is extremely rare to ﬁnd an HG-DCIS in a LG-
IDC, as well as a LG-DCIS in an HG-IDC; (ii) in tubular
carcinoma we see frequently an in situ component like FEA
or LG-DCIS cribriform type. Also, growth characteristics
and rates of expression of sex hormones, oncogenes, and
tumor suppressor genes suggest that LG-DCIS is a precursor
of LG-IDC and HG-DCIS is a precursor of HG-IDC [41, 42].International Journal of Surgical Oncology 7
Table 3: Cancerogenesis models.
Linear model of progression
(1) TDLU ADH LG-DCIS LG-IDC Metastases
Parallel model of progression
FEA
(2) TDLU HG-IDC HG-DCIS Metastases
TDLU UDH ADH or FEA LG-DCIS HG-DCIS IDC Metastases
Table 4: Classiﬁcation of DCIS based on biologic potential [44].
LG-DCIS
- Low nuclear grade
- ER/PgR positive  
- No comedo necrosis
- Low Ki67
- p53 normal 
- bcl2 upregulated
Ductal 
cell
Dysplastic 
cell (?)
HG-DCIS
- High nuclear grade
- ER/PgR negative
- Comedo necrosis
- High Ki67
- p53 mutations
- LOH 11q13
- Psoriasin (S-100A7) and MMPs upregulated
Well differentiated 
IDC
Poorly 
differentiated IDC
- c-erbB2 negative
- c-erbB2 positive
Histology:
Histology:
Molecular markers:
Molecular markers:
These data suggest that there may be multiple pathways for
the evolution of IPLs and IDC. In various tissues, a linear
multistep progression between various preinvasive stages,
which end in invasive cancer, is recognizable: in colonic
mucosa, for example, there is a linear multistep model
from normal epithelium to invasive carcinoma through
the sequence hyperproliferative epithelium, adenoma, car-
cinoma, and any morphological step is related to a speciﬁc
genetic alteration [49]. In breast cancer, the linear model
undoubtedly oversimpliﬁes a complex process. There is no
morphologicalormolecularevidencethatLG-DCISprogress
into an HG-DCIS, or into HG-IDC. The model that results
from morphological and molecular data is horizontal (or
parallel), and it is done by two or several pathways (Table 3).
For this reason, the DIN system is not a progression
through diﬀerent grades, like the intraepithelial neoplasia
in other tissue (for example, the CIN system of cervical
cancer),butaclassiﬁcationofdiﬀerentintraductalneoplastic
conditions, each of these are not an obligate precursor of
IDC.
The DCIS classiﬁcation of Wiechmann and Kuerer [44],
based on biological potential to progress into IDC, shows
twoparallelpathwaysof progression withdiﬀerent histologic
characteristics and molecular markers. Between these two
pathways, there is a presumptive common progenitor, a
dysplastic cell,n o tb e t t e rc h a r a c t e r i z e d( Table 4).
In IDC, recent studies have led to a molecular classiﬁ-
cation based on the biological characteristics of the tumor
rather than limited to morphological analysis. Perou [23]
and Sotiriou et al. [24] identiﬁed molecular subtypes of
invasive breast cancer based on an intrinsic gene signature.
Many studies have aimed to identify an IHC proﬁle that can
act as a surrogate for gene array analysis, and it appears that
a ﬁve-marker panel of estrogen receptor (ER), progesterone
receptor (PR), c-erbB2, cytokeratin 5/6, and EGFR shows
ability to categorise invasive cancers to their molecular
subtype [50]. Much less attention has been focused on
dissecting the biological subtypes of DCIS, and there are
discrepancies in the results. Thus, whereas several studies
report the existence of a basal subtype of DCIS [25, 51],
one gene array study found no ﬁrm evidence of this
category of DCIS or it is much less frequent [51]. There
are also other discrepancies in the relative frequency of
subtypes between the in situ and invasive disease. It has been
recognized, for example, that there is a higher frequency
of c-erbB2-positive DCIS compared with c-erbB2-positive
IDC [52]. The diﬀerence in expression of c-erbB2 is actually
inexplicable:thehypothesesadvancedarethattheexpression8 International Journal of Surgical Oncology
isswitchedoﬀduringinvasionorthatmanyc-erbB2-positive
DCIS do not transform to IDC.
6. Conclusions
DiagnosisandreproducibilityofproposedcriteriaofIPLsare
complex. This is testiﬁed by terminological confusion, with a
large number of designations for the same entity. To render
the issue even more controversial, it is not clear whether
some of these entities really occur in practice. Interobserver
agreement in diagnosis of intermediate lesions is low. The
DIN system uniﬁes the terminology, while it may have the
additional advantage to decrease the anxiety and emotional
stress of patients.
Morphologicalcomplexityisreﬂectedbythelargevariety
ofmolecularﬁndingsdescribedbyanumberofstudiesinthe
last twenty years. Some of these alterations are conﬁrmed by
diﬀerent studies, and their comparison with diﬀerent clinical
entities provides much information about their nature and
propensity for progression. UDH or epitheliosis is probably
a benign process, while other IPLs (ADH, LG-DCIS, HG-
DCIS, FEA) are neoplastic processes. ADH and FEA shares
many alterations with LG-DCIS and LG-IDC, while HG-
DCIS share many alterations with HG-IDC. Probably, the
modelofbreastcarcinogenesisismorecomplexthaninother
tissues, because the results of the molecular studies suggest
parallel diﬀerent pathways of carcinogenesis. By this point of
view, the DIN system is not a progression through diﬀerent
additional steps, like the intraepithelial neoplasia in other
tissues (e.g., the CIN system for uterine cervix cancer), but
a classiﬁcation of diﬀerent conditions, which are not obligate
precursors of IDC.
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